RedHill Biopharma Ltd (RDHL)

[Amatuer17]

Yes - it is dual sword.

However based on CYDY decision to reduce patient nos from 300 to 150 to 30 - it seems if the results are good - fda is ready to relax rules.

RDHL is very conservative and the fact that they has stopped earlier enrollment for new guidance - I think the probability of trial stopping based on 210 patients is decent

If that happens - the BO chances are very high - all BP are after Crohn's